image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.23
2.5 %
$ 52.9 M
Market Cap
-1.1
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one RPID stock under the worst case scenario is HIDDEN Compared to the current market price of 1.23 USD, Rapid Micro Biosystems, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one RPID stock under the base case scenario is HIDDEN Compared to the current market price of 1.23 USD, Rapid Micro Biosystems, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one RPID stock under the best case scenario is HIDDEN Compared to the current market price of 1.23 USD, Rapid Micro Biosystems, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
22.5 M REVENUE
31.44%
-56.6 M OPERATING INCOME
10.53%
-52.5 M NET INCOME
13.71%
-45.1 M OPERATING CASH FLOW
23.00%
42.2 M INVESTING CASH FLOW
145.10%
149 K FINANCING CASH FLOW
-78.50%
7.6 M REVENUE
14.90%
-12 M OPERATING INCOME
10.01%
-11.3 M NET INCOME
9.98%
-8.6 M OPERATING CASH FLOW
15.01%
-6.54 M INVESTING CASH FLOW
-26.34%
61 K FINANCING CASH FLOW
710.00%
Balance Sheet Rapid Micro Biosystems, Inc.
image
Current Assets 120 M
Cash & Short-Term Investments 92.1 M
Receivables 5.58 M
Other Current Assets 22.8 M
Non-Current Assets 23 M
Long-Term Investments 2.91 M
PP&E 19.1 M
Other Non-Current Assets 1.05 M
Current Liabilities 19 M
Accounts Payable 1.97 M
Short-Term Debt 1.23 M
Other Current Liabilities 15.8 M
Non-Current Liabilities 6.48 M
Long-Term Debt 6.21 M
Other Non-Current Liabilities 263 K
EFFICIENCY
Earnings Waterfall Rapid Micro Biosystems, Inc.
image
Revenue 22.5 M
Cost Of Revenue 28 M
Gross Profit -5.48 M
Operating Expenses 51.1 M
Operating Income -56.6 M
Other Expenses -4.1 M
Net Income -52.5 M
RATIOS
-24.36% GROSS MARGIN
-24.36%
-251.18% OPERATING MARGIN
-251.18%
-232.99% NET MARGIN
-232.99%
-44.47% ROE
-44.47%
-36.57% ROA
-36.57%
-47.93% ROIC
-47.93%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Rapid Micro Biosystems, Inc.
image
Net Income -52.5 M
Depreciation & Amortization 3.1 M
Capital Expenditures -1.84 M
Stock-Based Compensation 4.75 M
Change in Working Capital 555 K
Others 1.96 M
Free Cash Flow -46.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Rapid Micro Biosystems, Inc.
image
RPID has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Rapid Micro Biosystems, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
41.4 K USD 1
0-3 MONTHS
142 K USD 4
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Dec 05, 2024
Bought 9.48 K USD
PEI MELINDA LITHERLAND
Director
+ 9120
1.0399 USD
1 month ago
Dec 03, 2024
Bought 10.9 K USD
PEI MELINDA LITHERLAND
Director
+ 10880
1 USD
1 month ago
Nov 27, 2024
Bought 20.9 K USD
PEI MELINDA LITHERLAND
Director
+ 19892
1.05 USD
1 month ago
Nov 26, 2024
Bought 112 USD
PEI MELINDA LITHERLAND
Director
+ 108
1.04 USD
5 months ago
Aug 08, 2024
Bought 45.3 K USD
Malloy Kirk
Director
+ 50000
0.9067 USD
5 months ago
Aug 07, 2024
Bought 7.8 K USD
WIRTJES SEAN M
CHIEF FINANCIAL OFFICER
+ 10000
0.78 USD
5 months ago
Aug 06, 2024
Bought 50.1 K USD
Kollender Richard S
Director
+ 65000
0.7712 USD
5 months ago
Aug 06, 2024
Bought 38.4 K USD
Spignesi Robert G. Jr.
PRESIDENT AND CEO
+ 50000
0.768 USD
1 year ago
Sep 06, 2023
Bought 9.89 K USD
WIRTJES SEAN M
CHIEF FINANCIAL OFFICER
+ 10000
0.9894 USD
1 year ago
Aug 15, 2023
Bought 19.5 K USD
Spignesi Robert G. Jr.
PRESIDENT AND CEO
+ 20000
0.9744 USD
1 year ago
Aug 08, 2023
Bought 31.4 K USD
Spignesi Robert G. Jr.
PRESIDENT AND CEO
+ 34000
0.9249 USD
1 year ago
May 17, 2023
Bought 279 USD
Spignesi Robert G. Jr.
PRESIDENT AND CEO
+ 300
0.93 USD
1 year ago
May 17, 2023
Bought 92.5 USD
Spignesi Robert G. Jr.
PRESIDENT AND CEO
+ 100
0.925 USD
1 year ago
May 17, 2023
Bought 92.4 USD
Spignesi Robert G. Jr.
PRESIDENT AND CEO
+ 100
0.924 USD
1 year ago
May 17, 2023
Bought 92.3 USD
Spignesi Robert G. Jr.
PRESIDENT AND CEO
+ 100
0.923 USD
1 year ago
May 17, 2023
Bought 1.29 K USD
Spignesi Robert G. Jr.
PRESIDENT AND CEO
+ 1400
0.92 USD
1 year ago
May 17, 2023
Bought 13.4 K USD
Spignesi Robert G. Jr.
PRESIDENT AND CEO
+ 14700
0.91 USD
1 year ago
May 17, 2023
Bought 2.72 K USD
Spignesi Robert G. Jr.
PRESIDENT AND CEO
+ 3000
0.905 USD
1 year ago
May 17, 2023
Bought 90.1 USD
Spignesi Robert G. Jr.
PRESIDENT AND CEO
+ 100
0.901 USD
1 year ago
May 17, 2023
Bought 178 USD
Spignesi Robert G. Jr.
PRESIDENT AND CEO
+ 200
0.89 USD
2 years ago
Jun 03, 2022
Bought 137 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 29398
4.6646 USD
2 years ago
Jun 02, 2022
Bought 29.6 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 5938
4.9868 USD
2 years ago
Jun 03, 2022
Bought 96.1 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 20602
4.6646 USD
2 years ago
Jun 02, 2022
Bought 96.1 K USD
CHENE DAVID
director:
+ 20602
4.6646 USD
2 years ago
Jun 02, 2022
Bought 20.8 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 4162
4.9868 USD
2 years ago
Jun 01, 2022
Bought 132 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 27703
4.7598 USD
2 years ago
May 31, 2022
Bought 60.1 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 11759
5.114 USD
2 years ago
May 27, 2022
Bought 4.64 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 882
5.2626 USD
2 years ago
Jun 01, 2022
Bought 92.4 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 19414
4.7598 USD
2 years ago
May 27, 2022
Bought 92.4 K USD
CHENE DAVID
director:
+ 19414
4.7598 USD
2 years ago
May 31, 2022
Bought 42.1 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 8241
5.114 USD
2 years ago
May 27, 2022
Bought 3.25 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 618
5.2626 USD
2 years ago
May 25, 2022
Bought 60.8 K USD
CHENE DAVID
director:
+ 12396
4.9027 USD
2 years ago
May 26, 2022
Bought 60.8 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 12396
4.9027 USD
2 years ago
May 25, 2022
Bought 73.8 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 16933
4.358 USD
2 years ago
May 26, 2022
Bought 42.6 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 8687
4.9027 USD
2 years ago
May 25, 2022
Bought 51.7 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 11867
4.358 USD
2 years ago
May 18, 2022
Bought 62.6 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 15875
3.9426 USD
2 years ago
May 17, 2022
Bought 169 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 40873
4.1335 USD
2 years ago
May 18, 2022
Bought 43.9 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 11125
3.9426 USD
2 years ago
May 17, 2022
Bought 43.9 K USD
CHENE DAVID
director:
+ 11125
3.9426 USD
2 years ago
May 17, 2022
Bought 118 K USD
KENNEDY LEWIS MANAGEMENT LP
10 percent owner
+ 28643
4.1335 USD
2 years ago
May 16, 2022
Bought 38 K USD
Spignesi Robert G. Jr.
President and CEO
+ 10000
3.795 USD
2 years ago
Mar 10, 2022
Bought 69.5 K USD
LOWENSTEIN INESE
director:
+ 10000
6.95 USD
3 years ago
Jul 19, 2021
Bought 2 M USD
Bain Capital Life Sciences Investors, LLC
10 percent owner
+ 100000
20 USD
3 years ago
Jul 19, 2021
Bought 3 M USD
Longitude Capital Partners II, LLC
10 percent owner
+ 150000
20 USD
7. News
Rapid Micro Biosystems to Present at 43ʳᵈ Annual J.P. Morgan Healthcare Conference LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference. globenewswire.com - 1 week ago
Rapid Micro Biosystems to Participate in the Stifel 2024 Healthcare Conference LEXINGTON, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2024 Healthcare Conference. globenewswire.com - 2 months ago
Rapid Micro Biosystems, Inc. (RPID) Q3 2024 Earnings Call Transcript Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q3 2024 Results Conference Call November 1, 2024 9:00 AM ET Company Participants Michael Beaulieu - CFA, VP, IR & Corporate Communications Robert Spignesi - President & CEO Sean Wirtjes - CFO Conference Call Participants Brendan Smith - TD Cowen Dan Arias - Stifel Operator Thank you for standing by. My name is Novi, and I will be your conference operator today. seekingalpha.com - 2 months ago
Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.26 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.31 per share a year ago. zacks.com - 2 months ago
Rapid Micro Biosystems Reports Third Quarter 2024 Financial Results LEXINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the third quarter ended September 30, 2024. globenewswire.com - 2 months ago
Rapid Micro Biosystems to Announce Third Quarter 2024 Financial Results on November 1, 2024 LEXINGTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2024 financial results prior to the market open on Friday, November 1, 2024. globenewswire.com - 2 months ago
Rapid Micro Biosystems to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024, in New York City. globenewswire.com - 4 months ago
Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago. zacks.com - 5 months ago
Rapid Micro Biosystems Reports Second Quarter 2024 Financial Results LEXINGTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2024. globenewswire.com - 5 months ago
Rapid Micro Biosystems to Announce Second Quarter 2024 Financial Results on August 2, 2024 LOWELL, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2024 financial results prior to the market open on Friday, August 2, 2024. globenewswire.com - 6 months ago
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.32 per share a year ago. zacks.com - 8 months ago
Rapid Micro Biosystems Reports First Quarter 2024 Financial Results Reports first quarter 2024 total revenue of $5.6 million , representing growth of 11% compared to first quarter 2023 globenewswire.com - 8 months ago
8. Profile Summary

Rapid Micro Biosystems, Inc. RPID

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 52.9 M
Dividend Yield 0.00%
Description Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Contact 1001 Pawtucket Boulevard West, Lowell, MA, 01854 https://www.rapidmicrobio.com
IPO Date July 15, 2021
Employees 193
Officers Mr. John J. Addington Wilson Chief Operating Officer Ms. Kristine Williams Senior Vice President of Product James Xu Vice President of Legal & Secretary Mr. Sean M. Wirtjes CPA Chief Financial Officer Mr. Michael Beaulieu C.F.A. Vice President of Investor Relations & Corporate Communications Mr. Michael Wysocki Senior Vice President of Sales & Marketing Mr. Robert G. Spignesi Jr. Chief Executive Officer, President & Director